As the regulator of MHC class I genes, NLRC5 could enable tumor cells to activate CD8+ T cells (Rodriguez et al., 2016; Lupfer et al., 2017), and its deficiency would impair tumor cell killing by CD8+ T cells, then promote tumor growth and metastasis (Staehli et al., 2012; Rodriguez et al., 2016). This evidence concerns the gene CD8A and neoplasm.